What is the evidence for prophylactic antibiotic treatment in patients with systemic vasculitides?

Current Opinion in Rheumatology

Volumn 23, Issue 3, 2011, Pages 311-316

  Kallenberg, Cees G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

co trimoxazole; hepatitis B virus; hepatitis C virus; Staphylococcus aureus; systemic vasculitis; Wegener's granulomatosis

Indexed keywords

ALPHA INTERFERON; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; NEUTROPHIL CYTOPLASMIC ANTIBODY; RIBAVIRIN; RITUXIMAB; STEROID;

ANAPHYLACTOID PURPURA; ANCA ASSOCIATED VASCULITIS; ANTIBIOTIC PROPHYLAXIS; AUTOIMMUNE DISEASE; CLINICAL FEATURE; CRYOGLOBULINEMIA; GIANT CELL ARTERITIS; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; MICROSCOPIC POLYANGIITIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; POLYARTERITIS NODOSA; PRIORITY JOURNAL; RELAPSE; REVIEW; STAPHYLOCOCCUS AUREUS; SYSTEMIC VASCULITIS; WEGENER GRANULOMATOSIS;

ANTI-BACTERIAL AGENTS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIGEN-ANTIBODY COMPLEX; HEPATITIS B; HEPATITIS C; HUMANS; POLYARTERITIS NODOSA; RECURRENCE; STAPHYLOCOCCAL INFECTIONS; SYSTEMIC VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 79955018806     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328344f323     Document Type: Review

References (50)

1. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides: the proposal of an international consensus conference. Arthritis Rheum 1994; 37:187-192. (Pubitemid 24065492)
2. Wegener F. On generalized septic vascular diseases [in German]. Verh Deut Pathol Ges 1936; 29:202-210.
3. Pagnoux C, Cohen P, Guillevin L. Vasculitides secondary to infections. Clin Exp Rheumatol 2006; 24 (2 Suppl. 41):S71-S81. (Pubitemid 43997101)
4. Rodriguez-Pla A, Stone JH. Vasculitis and systemic infections. Curr Opin Rheumatol 2006; 18:39-47. (Pubitemid 43740404)
5. Lefebvre M, Grossi O, Agard C, et al. Systemic immune presentations of Coxiella burnetii infection (Q fever). Semin Arthritis Rheum 2010; 39:405-409.
6. Ghosh K, Pradhan V, Ghosh K. Background noise of infection for using ANCA as a diagnostic tool for vasculitis in tropical and developing countries. Parasitol Res 2008; 102:1093-1095.
7. Choi HK, Lamprecht P, Niles JL, et al. Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and antiproteinase .3. antibodies. Arthritis Rheum 2000; 43:226-231. (Pubitemid 30368232)
8. Hellmich B, Ehren M, Lindstaedt M, et al. Anti-MPO-ANCA-positive microscopic polyangiitis following subacute bacterial endocarditis. Clin Rheumatol 2001; 20:441-443. (Pubitemid 33130484)
9. Bonaci-Nikolic B, Andrejevic S, Pavlovic M, et al. Prolonged infections associated with antineutrophil cytoplasmic antibodies specific to proteinase .3. and myeloperoxidase: diagnosis and therapeutic challenge. Clin Rheumatol 2010; 29:893-904.
10. Weyand C, Goronzy JJ. Medium-and large-Vessel vasculitis. N Engl J Med 2003; 349:160-169.
11. Wagner AD, Gé rard HC, Fresemann T, et al. Detection of Chlamydia pneumoniae in giant cell vasculitis and correlation with the topographic arrangement of tissue-infiltrating dendritic cells. Arthritis Rheum 2000; 43:1543-1551. (Pubitemid 30452475)
12. Duhaut P, Bosshard S, Ducroix JP. Is giant cell arteritis an infectious disease? Biological and epidemiological evidence. Presse Med 2004; 33:1403-1408. (Pubitemid 39540595)
13. Cooper RJ, D'Arcy S, Kirby M, et al. Infection and temporal arteritis: a PCRbased study to detect pathogens in temporal artery biopsy specimens. J Med Virol 2008; 80:501-505. (Pubitemid 351206900)
14. Njau F, Ness T, Wittkop U, et al. No correlation between giant cell arteritis and Chlamydia pneumoniae infection: investigation of 189 patients by standard and improved PCR methods. J Clin Microbiol 2009; 47:1899-1901.
15. Kumar Chauhan S, Kumar Tripathy N, Sinha N, et al. Cellular and humoral immune responses to mycobacterial heat shock protein-65 and its human homologue in Takayasu's arteritis. Clin Exp Immunol 2004; 138:547-553. (Pubitemid 39573638)
16. Guillevin L, Mahr A, Callard P, et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 2005; 84:313-322. (Pubitemid 41368484)
17. Pagnoux C, Seror R, Henegar C, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum 2010; 62:616-626.
18. Canada R, Chaudry S, Gaber L, et al. Polyarteritis nodosa and cryoglobulinemic glomerulonephritis related to chronic hepatitis C. Am J Med Sci 2006; 331:329-333.
19. Esper F, Shapiro ED, Weibel C, et al. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis 2005; 191:499-502. (Pubitemid 40216663)
20. Johnson RM, Barbarini G, Barbaro G. Kawasaki-like syndromes and other vasculitic syndromes in HIV-infected patients. AIDS 2003; 17 (Suppl. 1): S77-S82. (Pubitemid 36667784)
21. MacNiel A, Holman RC, Yorita KL, et al. Evaluation of seasonal patterns of Kawasaki syndrome-and rotavirus-associated hospitalization in California and New York. BMC Pediatr 2009; 9:65.
22. Leung DY, Meissner HC, Shulman ST, et al. Prevalence of superantigensecreting bacteria in patients with Kawasaki disease. J Pediatr 2002; 140:742-746. (Pubitemid 34666695)
23. Ramos-Casals M, Munoz S, Medina F, et al. Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (the HISPAMEC Registry). J Rheumatol 2009; 36:1442-1448.
24. Saadoun D, Landau DA, Calabrese LH, Cacoub PP. Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation. Rheumatology (Oxford) 2007; 46:1234-1242. (Pubitemid 47244492)
25. Landau DA, Scerra S, Sene D, et al. Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryglobulinemic vasculitis treated with antiviral therapy. J Rheumatol 2010; 37:615-621.
26. Alfredo CS, Nunes NA, Len CA, et al. Henoch-Schö nlein purpura: recurrence and chronicity. J Pediatr (Rio J) 2007; 83:177-180. (Pubitemid 46556638)
27. Mytinger JR, Patterson JW, Thibault ES, et al. Henoch-Schö nlein purpura associated with Helicobacter pylori infection in a child. Pediatr Dermatol 2008; 25:630-632.
28. Uggeri S, Fabbian F, Catizone L. Henoch-Schö nlein purpura due to methicillin-sensitive Staphylococcus aureus bacteremia from central venous catheterization. Clin Exp Nephrol 2008; 12:219-223.
29. Kravitz GR, Dries DJ, Peterson ML, Schlievert PM. Purpura fulminans duet to Staphylococcus aureus. Clin Infect Dis 2005; 40:941-947. (Pubitemid 40418298)
30. Stegeman CA, Cohen Tervaert JW, Sluiter WJ, et al. Association of nasal carriage of Staphylococcus aureus and higher relapse in Wegener's granulomatosis. Ann Intern Med 1994; 120:12-17. (Pubitemid 24011495)
31. Laudien M, Gadola SD, Podschun R, et al. Nasal carriage of Staphylococcus aureus and endonasal activity in Wegener's granulomatosis as compared to rheumatoid arthritis and chronic rhinosinusitis with nasal polyps. Clin Exp Rheumatol 2010; 28 (1 Suppl. 57):51-55.
32. Zycinska K, Wardyn KA, Zielonka TM, et al. Chronic crusting, nasal carriage of Staphylococcus aureus and relapse rate in pulmonary Wegener's granulomatosis. J Physiol Pharmacol 2008; 59 (Suppl. 6):825-831.
33. Popa ER, Stegeman CA, Bos NA, et al. Staphylococcal superantigens and T cell expansion in Wegener's granulomatosis. Clin Exp Immunol 2003; 132:496-504. (Pubitemid 36713957)
34. Richter AG, Stockley RA, Harper L, Thickett DR. Pulmonary infection in Wegener granulomatosis and idiopathic pulmonary fibrosis. Thorax 2009; 64:692-697.
35. Popa ER, Stegeman CA, Kallenberg CGM, Tervaert JW. Staphylococcus aureus and Wegener's granulomatosis. Arthritis Res 2002; 4:77-79.
36. Chen M, Kallenberg CGM. ANCA-associated vasculitides: advances in pathogenesis and treatment. Nat Rev Rheumatol 2010; 6:653-664.
37. Popa ER, Stegeman CA, Abdulahad WH, et al. Staphylococcal toxic-shocksyndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis. Rheumatology (Oxford) 2007; 46:1029-1033. (Pubitemid 47062516)
38. Pendergraft WF, Preston GA, Shah RR, et al. Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med 2004; 10:72-79. (Pubitemid 38524701)
39. DeRemee RA, McDonald TJ, Weiland RH. Wegener's granulomatosis: observations on treatment with antimicrobial agents. Mayo Clin Proc 1985; 60:27-32. (Pubitemid 15199622)
40. Roberts DE, Curd JG. Sulfonamides as antiinflammatory agents in the treatment of Wegener's granulomatosis. Arthritis Rheum 1990; 33:1590-1593. (Pubitemid 20362106)
41. West BC, Todd JR, King JW. Wegener granulomatosis and trimethoprimsulfamethoxazole. Complete remission after a twenty-year course. Ann Intern Med 1987; 106:840-842. (Pubitemid 17078978)
42. Israel HL. Sulfamethoxazole-trimethoprim therapy for Wegener's granulomatosis. Arch Intern Med 1988; 148:2293-2295.
43. Valeriano-Marcet J, Spiera H. Treatment of Wegener's granulomatosis with sulfamethoxazole-trimethoprim. Arch Intern Med 1991; 151:1649-1652.
44. McRae D, Buchanan G. Long-term sulfamethoxazole-trimethoprim in Wegener's granulomatosis. Arch Otolaryngol Head Neck Surg 1993; 119:103-105. (Pubitemid 23033260)
45. Georgi J, Ulmer M, Gross WL. Cotrimoxazole in Wegener's granulomatosis: a prospective study [in German]. Immun Infekt 1991; 19:97-98.
46. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CGM. Trimethoprimsulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996; 335:16-20.
47. De Groot K, Reinhold-Keller E, Tatsis E, et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis: methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum 1996; 39:2052-2061.
48. Reinhold-Keller E, De Groot K, Rudert H, et al. Response to trimethoprim/ sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. QJM 1996; 89:15-23. (Pubitemid 26023960)
49. Zycinska K, Wardyn KA, Zielonka TM, et al. Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement. Eur J Med Res 2009; 14 (Suppl. 4):265-267.
50. Kain R, Exner M, Brandes R, et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 2008; 14:1088-1096.